RESUMEN
Type 2 diabetes (T2D) represents a major medical and public health problem. The ability to prevent or delay T2D by modifying some of its risk factors has been hypothesized for several decades. Indeed, the slow and gradual deterioration of glycaemia prior to the diabetes diagnosis constitutes a period during which interventions could be effective in preventing T2D. Lifestyle modifications demonstrated that modest weight loss (at least 7% of initial weight) and moderate to intense physical activity of at least 150 minutes per week, markedly and significantly delayed the onset of T2D in subjects at high risk of developing the disease. Pharmacological interventions indicated that metformin should be considered, particularly in young patients (< 60 years) with a body mass index ≥ 35 kg/m², and in women with a history of gestational diabetes. Bariatric surgery, which allows significant weight loss in subjects with severe or morbid obesity, has also demonstrated important preventive effectiveness and metabolic surgery in now considered in at-risk patients with less severe obesity. In conclusion, in overweight or obese adults at high risk of developing T2D, treatment aimed at losing weight (including bariatric surgery) and increasing physical activity should be implemented, and a pharmacotherapy might be considered case by case.
Le diabète de type 2 (DT2) constitue un problème majeur, tant au niveau médical individuel qu'en termes de santé publique. La capacité de prévenir ou retarder le DT2 en modifiant certains facteurs de risque est une hypothèse envisagée depuis plusieurs décennies. En effet, la lente et graduelle détérioration de la glycémie avant le diagnostic de diabète constitue une période au cours de laquelle des interventions pourraient se révéler efficaces. Les modifications de comportement concernant le mode de vie ont démontré qu'une perte de poids modeste (au moins 7 % du poids initial) et une activité physique modérée à intense d'au moins 150 minutes par semaine retardaient, de manière importante et significative, l'apparition du DT2 chez des sujets à haut risque de développer la maladie. Au niveau médicamenteux, la metformine s'est également révélée efficace, en particulier chez les patients jeunes (< 60 ans) avec un indice de masse corporelle ≥ 35 kg/m², et chez les femmes avec des antécédents de diabète gestationnel. La chirurgie bariatrique, qui permet d'obtenir une perte de poids importante chez les sujets avec obésité sévère ou morbide, a également démontré une grande efficacité pour prévenir la survenue d'un DT2. Une chirurgie métabolique est même maintenant envisagée chez des sujets à risque avec une obésité moins sévère. En conclusion, chez les adultes en surpoids ou obèses à haut risque de développer un DT2, une prise en charge visant à perdre du poids (y compris via la chirurgie bariatrique) et augmenter l'activité physique devrait être mise en place, couplée le cas échéant à une approche pharmacologique.
Asunto(s)
Diabetes Mellitus Tipo 2 , Femenino , Humanos , Cirugía Bariátrica , Diabetes Mellitus Tipo 2/prevención & control , Diabetes Mellitus Tipo 2/complicaciones , Ejercicio Físico , Hipoglucemiantes/uso terapéutico , Estilo de Vida , Obesidad/complicaciones , Factores de Riesgo , Pérdida de Peso , Masculino , Adulto , Persona de Mediana EdadRESUMEN
BACKGROUND AND AIMS: In 2009, the Institute of Medicine (IOM) issued recommendations for gestational weight gain (GWG) based on body mass index (BMI). Several studies have challenged those recommendations for women with obesity, considering them too liberal and advising more limited weight gain - or even weight loss - during pregnancy to improve maternal and neonatal outcomes. Our aim was to study how gestational weight gain in women with obesity impacted maternal and fetal complications in the Belgian population. We did this by comparing the results from two groups of patients with obesity: those who met the 2009 IOM standards and those who satisfied the stricter recommendations suggested by other authors. MATERIALS AND METHODS: This is a retrospective cohort study using data collected at the Centre d'Epidémiologie Périnatale (CEpiP) from obese (BMI ≥ 30 kg/m2) pregnant women with live singleton deliveries between 2010 and 2019 in Wallonia-Brussels Federation (n = 65,314). RESULTS: Compared to obese patients whose GWG satisfied the IOM standards, those with GWG meeting the stricter recommendations had lower rates of gestational hypertension (7.1 % vs. 10.1 %; p = 0.0059), cesarean section (22.1 % vs. 26.3 %; p = 0.0074), and macrosomia (12.0 % vs. 17.7 %; p < 0.0001). There was no significant difference in the rate of preterm delivery (6.9 % vs 5.8 %; p = 0.12) or small-for-gestational-age births (7.2 % vs. 6.2 %; p = 0.16). CONCLUSION: Gestational weight gain below that currently recommended by the IOM appears beneficial to the health of mothers with obesity and their children. These data, from our population, further challenge the standards proposed since 2009.
Asunto(s)
Ganancia de Peso Gestacional , Obesidad , Complicaciones del Embarazo , Humanos , Femenino , Embarazo , Estudios Retrospectivos , Adulto , Obesidad/complicaciones , Índice de Masa Corporal , Guías de Práctica Clínica como Asunto , Bélgica , Resultado del Embarazo , Macrosomía FetalRESUMEN
Patients with type 2 diabetes (T2D) are frequently exposed to comorbidities, mainly cardiovascular complications. Thus, a polypharmacy is often mandatory, targeting not only T2D but also comorbidities such as coronary artery disease and heart failure. Interestingly, some drugs improve glucose control, cardiovascular prognosis and heart failure outcome. This versatility may cause trouble regarding prescriptions by practitioners, especially because of the restricted conditions for the reimbursement in Belgium. This clinical vignette aims at discussing the path of pharmacotherapy for a patient with T2D who suffers from a myocardial infarction and subsequently develops a heart failure. It will mainly focus on the place of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporters 2 (gliflozins) as well as the potential of their combination in this context, considering the current restrictions for the reimbursement.
Le patient avec un diabète de type 2 (DT2) est souvent exposé à diverses comorbidités, notamment cardiovasculaires. Dès lors, une polymédication est souvent nécessaire, ciblant le DT2 lui-même, mais aussi les comorbidités comme une coronaropathie et une insuffisance cardiaque. De façon intéressante, certaines médications améliorent à la fois le contrôle glycémique, le pronostic cardiovasculaire et le devenir de l'insuffisance cardiaque. Cette polyvalence peut jeter le trouble en ce qui concerne les prescriptions chez les praticiens, notamment en lien avec les conditions restrictives de remboursement en Belgique. Cette vignette clinique a pour but d'illustrer le cheminement de la pharmacothérapie d'un patient avec un DT2 qui présente un infarctus du myocarde puis, secondairement, une insuffisance cardiaque. Elle ciblera surtout la place des agonistes des récepteurs du glucagon-like peptide-1 et des inhibiteurs des cotransporteurs sodium-glucose de type 2 (gliflozines), et expliquera l'intérêt de leur combinaison dans ce contexte en tenant compte des conditions actuelles de remboursement.
Asunto(s)
Enfermedades Cardiovasculares , Sistema Cardiovascular , Enfermedad de la Arteria Coronaria , Diabetes Mellitus Tipo 2 , Insuficiencia Cardíaca , Humanos , Diabetes Mellitus Tipo 2/complicaciones , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Hipoglucemiantes/uso terapéutico , Insuficiencia Cardíaca/complicaciones , Enfermedad de la Arteria Coronaria/complicaciones , Receptor del Péptido 1 Similar al Glucagón/agonistas , Enfermedades Cardiovasculares/complicacionesRESUMEN
The concept of «metabolic syndrome¼ was brought to the forefront in the early 2000s in international literature, but this interest seems to have faded somewhat in recent years. However, this constellation of cardiovascular risk factors should not be neglected. Taken individually, they hardly seem problematic, but when they are present within the same individual, they significantly increase the risk of cardiovascular morbidity and mortality. This clinical vignette aims to draw attention to the usefulness of the search for metabolic syndrome in clinical practic.
Le concept de «syndrome métabolique¼ a été mis en avant de la scène au début des années 2000 dans la littérature internationale, mais cet intérêt semble s'être quelque peu estompé au cours des dernières années. Il convient cependant de ne pas négliger cette constellation de facteurs de risque cardiovasculaire qui, pris individuellement, ne paraissent guère problématiques, mais qui, lorsqu'ils co-existent chez une même personne, augmentent sensiblement le risque de morbi-mortalité. Cette vignette clinique a pour but d'attirer l'attention sur l'importance de la recherche d'un syndrome métabolique dans la pratique clinique.
Asunto(s)
Enfermedades Cardiovasculares , Diabetes Mellitus Tipo 2 , Síndrome Metabólico , Humanos , Síndrome Metabólico/complicaciones , Síndrome Metabólico/diagnóstico , Síndrome Metabólico/metabolismo , Factores de Riesgo , Enfermedades Cardiovasculares/etiología , Diabetes Mellitus Tipo 2/complicacionesRESUMEN
AIMS/HYPOTHESIS: We aimed to investigate the association between the abundance of Dysosmobacter welbionis, a commensal gut bacterium, and metabolic health in human participants with obesity and diabetes, and the influence of metformin treatment and prebiotic intervention. METHODS: Metabolic variables were assessed and faecal samples were collected from 106 participants in a randomised controlled intervention with a prebiotic stratified by metformin treatment (Food4Gut trial). The abundance of D. welbionis was measured by quantitative PCR and correlated with metabolic markers. The in vitro effect of metformin on D. welbionis growth was evaluated and an in vivo study was performed in mice to investigate the effects of metformin and D. welbionis J115T supplementation, either alone or in combination, on metabolic variables. RESULTS: D. welbionis abundance was unaffected by prebiotic treatment but was significantly higher in metformin-treated participants. Responders to prebiotic treatment had higher baseline D. welbionis levels than non-responders. D. welbionis was negatively correlated with aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels and fasting blood glucose levels in humans with obesity and type 2 diabetes. In vitro, metformin had no direct effect on D. welbionis growth. In mice, D. welbionis J115T treatment reduced body weight gain and liver weight, and improved glucose tolerance to a better level than metformin, but did not have synergistic effects with metformin. CONCLUSIONS/INTERPRETATION: D. welbionis abundance is influenced by metformin treatment and associated with prebiotic response, liver health and glucose metabolism in humans with obesity and diabetes. This study suggests that D. welbionis may play a role in metabolic health and warrants further investigation. CLINICAL TRIAL: NCT03852069.
Asunto(s)
Clostridiales , Diabetes Mellitus Tipo 2 , Metformina , Humanos , Animales , Ratones , Metformina/uso terapéutico , Metformina/farmacología , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Obesidad/tratamiento farmacológico , Dieta Alta en GrasaRESUMEN
OBJECTIVE: Human functional genomics has proven powerful in discovering drug targets for common metabolic disorders. Through this approach, we investigated the involvement of the purinergic receptor P2RY1 in type 2 diabetes (T2D). METHODS: P2RY1 was sequenced in 9,266 participants including 4,177 patients with T2D. In vitro analyses were then performed to assess the functional effect of each variant. Expression quantitative trait loci (eQTL) analysis was performed in pancreatic islets from 103 pancreatectomized individuals. The effect of P2RY1 on glucose-stimulated insulin secretion was finally assessed in human pancreatic beta cells (EndoCßH5), and RNA sequencing was performed on these cells. RESULTS: Sequencing P2YR1 in 9,266 participants revealed 22 rare variants, seven of which were loss-of-function according to our in vitro analyses. Carriers, except one, exhibited impaired glucose control. Our eQTL analysis of human islets identified P2RY1 variants, in a beta-cell enhancer, linked to increased P2RY1 expression and reduced T2D risk, contrasting with variants located in a silent region associated with decreased P2RY1 expression and increased T2D risk. Additionally, a P2RY1-specific agonist increased insulin secretion upon glucose stimulation, while the antagonist led to decreased insulin secretion. RNA-seq highlighted TXNIP as one of the main transcriptomic markers of insulin secretion triggered by P2RY1 agonist. CONCLUSION: Our findings suggest that P2RY1 inherited or acquired dysfunction increases T2D risk and that P2RY1 activation stimulates insulin secretion. Selective P2RY1 agonists, impermeable to the blood-brain barrier, could serve as potential insulin secretagogues.
Asunto(s)
Diabetes Mellitus Tipo 2 , Islotes Pancreáticos , Humanos , Diabetes Mellitus Tipo 2/genética , Diabetes Mellitus Tipo 2/metabolismo , Insulina/metabolismo , Islotes Pancreáticos/metabolismo , Genómica , Glucosa/metabolismo , Receptores Purinérgicos P2Y1/genética , Receptores Purinérgicos P2Y1/metabolismoRESUMEN
Dietary management of type 2 diabetes is essential to improve glycaemic control et reduce risk of diabetes complications. Key recommendations for people with diabetes are largely similar to those for the general population. Overweight or obese diabetic persons should be supported with evidence-based treatments to achieve and maintain weight loss. A wide range of carbohydrate intakes are acceptable and diets with a low glycaemic index or low glycaemic load may be recommended, provided their composition is consistent with overall diet recommendations for dietary fibers, sugars, saturated fats and proteins. It is also important to consume minimally processed plant foods, such as whole grains, vegetables, whole fruits, legumes, while reducing the consumption of red and processed meats, sodium and sugar-sweetened beverages.
La prise en charge nutritionnelle du diabète de type 2 est essentielle afin d'améliorer l'équilibre glycémique et réduire le risque de complications liées au diabète. Les principales recommandations diététiques pour les personnes diabétiques sont largement comparables à celles prodiguées dans la population générale. Les sujets diabétiques en surpoids ou obèses devraient bénéficier de prises en charge validées pour obtenir et maintenir une perte de poids. Un apport en glucides très variable est autorisé, avec des aliments à charge glycémique faible, et une composition adéquate en fibres, sucres, acides gras saturés et protéines. Il est important de réduire la consommation d'aliments transformés et de favoriser les céréales complètes, les produits végétaux (fruits et légumes), tout en limitant l'apport en viandes, sel et boissons sucrées.
Asunto(s)
Diabetes Mellitus Tipo 2 , Humanos , Diabetes Mellitus Tipo 2/terapia , Verduras , Alimentos Procesados , Frutas , CarneRESUMEN
Malaises are often attributed to hypoglycaemia in nondiabetic people who don't have any other serious medical problem. Reactive hypoglycaemia, the most frequent one, may be considered as a functional disorder. However, its diagnosis is often overused, because not really demonstrated in most instances. The diagnosis of hypoglycaemia should be structured, based upon the Whipple triad. First, the medical interrogatory must search for adrenergic and neuroglucopenic symptoms that suggest hypoglycaemia. Second, if the malaise is due to a hypoglycaemia, it should resume rapidly after the administration of sugar. Third, hypoglycaemia must be confirmed by a measurement of a low glucose level at the time of a malaise. The latter approach is facilitated by the use of home blood monitoring, a strategy that is now preferred to the use of an oral glucose tolerance test, a non-physiological test far from real-life conditions. When the diagnosis is made based upon this triad, the medical interview should precise the severity of the symptoms and focus on the chronology of the malaises, typically 2-3 hours after a sugar-enriched meal in case of a reactive hypoglycaemia. Therapeutic approach of this functional disorder mostly relies on dietary advices.
La survenue de malaises est souvent attribuée à une hypoglycémie chez des personnes non diabétiques et, a priori, sans autre problème de santé. L'hypoglycémie réactionnelle, la plus fréquente, peut être considérée comme un trouble fonctionnel. Son diagnostic est, cependant, souvent galvaudé, car l'hypoglycémie n'est habituellement pas authentifiée. Le diagnostic d'hypoglycémie doit se faire de façon structurée en se basant sur la «triade de Whipple¼. Tout d'abord, l'anamnèse doit rechercher les symptômes évocateurs d'hypoglycémie, adrénergiques et neuroglucopéniques. Ensuite, s'il s'agit bien d'une hypoglycémie, le malaise doit disparaître rapidement après resucrage. Enfin, l'hypoglycémie doit être authentifiée par une mesure d'une valeur basse au moment d'un malaise. Cette confirmation a été facilitée par l'utilisation des lecteurs de glycémie, une stratégie qui est dorénavant préférée à la réalisation d'une hyperglycémie provoquée par voie orale, test non physiologique fort éloigné des conditions de vraie vie. Une fois le diagnostic posé sur cette triade, l'anamnèse doit faire préciser, outre la sévérité des malaises, leur chronologie, typiquement 2-3 heures après un repas riche en glucides dans le cas d'une hypoglycémie réactive. Le traitement de ce trouble fonctionnel repose principalement sur des mesures diététiques.
Asunto(s)
Hipoglucemia , Humanos , Hipoglucemia/diagnóstico , Hipoglucemia/etiología , Hipoglucemia/terapia , Diagnóstico Diferencial , Azúcares/uso terapéutico , GlucemiaRESUMEN
Both physicians and patients dream of an efficacious and safe pharmacological approach to treat obesity. Unfortunately, most anti-obesity drugs prescribed since the fifties were associated with an unfavourable risk profile that led to numerous withdrawals. Medications issued from pharmaco-chemistry that mainly target brain amines to reduce appetite have been abandoned because of potential cardiovascular and neuropsychiatric toxicities. More recently, biological medications emerged, especially GLP-1 (Glucagon-Like Peptide-1) receptor agonists, well-known to manage type 2 diabetes and now recommended at higher doses for the treatment of obesity (liraglutide, semaglutide). A dual agonist that targets both GLP-1 and GIP (Glucose-dependent Insulinotropic Polypeptide) receptors (tirzepatide) appears to be even more potent as glucose-lowering agent and is currently tested as an anti-obesity agent. Many other pharmacological approaches are currently investigated but they should not mask the importance of life-style measurements.
Médecins et patients rêvent d'une approche pharmacologique efficace et sûre pour traiter l'obésité. Hélas, la plupart des médicaments anti-obésité testés depuis les années 50 ont été grevés d'un profil de risque défavorable, ce qui a amené de nombreux retraits du marché. Les médicaments issus de la pharmacochimie ciblant principalement les amines cérébrales pour freiner l'appétit ont été abandonnés en raison de leur toxicité potentielle, cardiovasculaire et neuropsychiatrique. Une nouvelle opportunité est offerte avec l'avènement de médicaments biologiques, en particulier des analogues du GLP-1 (Glucagon-Like Peptide-1) bien connus pour traiter le diabète de type 2 et aussi commercialisés à plus fortes doses pour traiter l'obésité (liraglutide, sémaglutide). Un agoniste double ciblant à la fois les récepteurs du GLP-1 et du GIP («Glucose-dependent Insulinotropic Polypeptide¼), le tirzépatide, s'avère encore plus puissant comme médicament antidiabétique et est actuellement testé comme agent anti-obésité. Un grand nombre d'autres approches pharmacologiques sont en cours d'investigation, mais toutes ces initiatives ne doivent pas scotomiser l'importance des mesures hygiéno-diététiques.
Asunto(s)
Fármacos Antiobesidad , Diabetes Mellitus Tipo 2 , Humanos , Fármacos Antiobesidad/farmacología , Fármacos Antiobesidad/uso terapéutico , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Péptido 1 Similar al Glucagón/farmacología , Péptido 1 Similar al Glucagón/uso terapéutico , Obesidad/tratamiento farmacológico , Glucosa/uso terapéutico , Receptor del Péptido 1 Similar al Glucagón/agonistas , Hipoglucemiantes/uso terapéuticoRESUMEN
BACKGROUND: Nutritional status of patients with disorders of consciousness (DoC) is poorly studied. OBJECTIVES: To evaluate the relationship between nutritional status (body mass index, daily calories intake) and clinical variables (level of consciousness, time since injury, diagnosis, etiology and spastic muscle overactivity; SMO,) in patients with prolonged DoCor emerging. Our main hypotheses are i) patients with lower level of consciousness (UWS) have worse nutritional status compared to patients in minimally conscious state (MCS) and ii) SMO could influence nutritional status. METHODS AND RESULTS: Among the 80 patients included in the study (19 UWS, 47 MCS, 14 emerging MCS; 43 ± 15 yo; 3 ± 4 years post-injury, 35 traumatic etiology, 34 females), 9% were at risk to be undernourished, with no differences between UWS and MCS. Patients without SMO had a higher BMI compared to patients with severe SMO. Compared to the recommended daily calories intake, patients with the highest BMI received less calories and patients with the lowest BMI received more calories. We observed a negative correlation between SMO (in lower limbs) and BMI. CONCLUSION: Our study shows that most patients are well nourished, independently from the level of consciousness. SMO may require additional calories in patients' daily needs; however, longitudinal studies are needed to explore the causal relationship between these variables.
Asunto(s)
Trastornos de la Conciencia , Estado Nutricional , Femenino , Humanos , Estudios Retrospectivos , Estudios Transversales , Trastornos de la Conciencia/etiología , Trastornos de la Conciencia/diagnóstico , Pronóstico , Estado Vegetativo Persistente/etiología , Estado Vegetativo Persistente/diagnóstico , Estado de Conciencia/fisiologíaRESUMEN
Tirzepatide is a unimolecular dual agonist of both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, which is developed as once-weekly injection for the treatment of type 2 diabetes. Because of the complementarity of action of the two incretins, tirzepatide showed, in a dose-dependent manner (5, 10 and 15 mg), a better efficacy (greater reduction in HbA1c and body weight) compared with placebo, basal insulin and two GLP-1 analogues (dulaglutide and semaglutide) in the SURPASS program. Its cardiovascular protection (versus dulaglutide) is currently tested in SURPASS-CVOT. Finally, studies for the treatment of obesity and metabolic associated fatty liver disease are also ongoing. Gastrointestinal tolerance of tirzepatide appears comparable to that of GLP-1 analogues, except more diarrhoea.
Le tirzépatide est un agoniste unimoléculaire double des récepteurs du polypeptide insulinotrope dépendant du glucose (GIP) et du Glucagon-Like Peptide-1 (GLP-1) développé, en injection hebdomadaire, pour le traitement du diabète de type 2. De par la complémentarité des 2 incrétines, il a montré, de façon dose-dépendante (5, 10 et 15 mg), une efficacité supérieure (plus forte réduction du taux d'HbA1c (hémoglobine glyquée) et du poids corporel) par rapport au placebo, à l'insuline basale et à 2 analogues du GLP-1 (dulaglutide et sémaglutide) dans le programme SURPASS. Sa protection cardiovasculaire (versus le dulaglutide) est actuellement testée dans SURPASS-CVOT. Enfin, des études sont en cours dans l'obésité et la stéatopathie hépatique. La tolérance digestive du tirzépatide est comparable à celle des analogues du GLP-1, hormis davantage de diarrhée.
Asunto(s)
Diabetes Mellitus Tipo 2 , Receptor del Péptido 1 Similar al Glucagón , Glucemia , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diabetes Mellitus Tipo 2/metabolismo , Polipéptido Inhibidor Gástrico , Péptido 1 Similar al Glucagón , Receptor del Péptido 1 Similar al Glucagón/agonistas , Humanos , Hipoglucemiantes/uso terapéuticoRESUMEN
Plasma C-peptide represents a direct measure of endogenous insulin secretion. The development of new assays for measuring C-peptide have made it possible to demonstrate that a low insulin secretion persists in 30 to 80% of subjects with type 1 diabetes (T1D), even among those with long-standing disease. Several studies have established that the persistence of B cell function of the islets of Langerhans is associated with a protection against the development of microvascular complications and resulted in a significant reduction in the prevalence of severe hypoglycaemia in people with T1D. Further studies are needed to clarify the underlying pathophysiological mechanisms and the therapeutic strategies that would maintain B-cell function and thus improve the quality of life of patients with T1D.
Le peptide-C plasmatique constitue une mesure directe de la sécrétion endogène d'insuline. Le développement de nouveaux dosages du peptide-C a permis de démontrer qu'il persiste chez 30 à 80 % des sujets diabétiques de type 1 (DT1) une faible sécrétion d'insuline, même sur le long terme. Plusieurs études ont établi que la persistance de la fonction B des îlots de Langerhans était associée à une protection contre le développement des complications microvasculaires et engendrait une réduction significative de la prévalence des hypoglycémies sévères chez les personnes DT1. Mais des études complémentaires sont encore nécessaires afin de préciser les mécanismes physiopathologiques sous-jacents et les stratégies thérapeutiques qui permettraient de maintenir la fonction de la cellule B et d'améliorer ainsi la qualité de vie des sujets avec un DT1.
Asunto(s)
Diabetes Mellitus Tipo 1 , Péptido C/metabolismo , Péptido C/uso terapéutico , Diabetes Mellitus Tipo 1/tratamiento farmacológico , Progresión de la Enfermedad , Humanos , Insulina/uso terapéutico , Secreción de Insulina , Calidad de VidaRESUMEN
BACKGROUND: Cardiovascular disease (CVD) is one of the leading causes of death in Belgium. Current strategies for the prevention and management of CVD focus on reducing low-density lipoprotein cholesterol (LDL-C) levels. This analysis assessed whether LDL-C goals, recommended by the European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines, were being achieved in a Belgian study population. METHODS: The cross-sectional, observational, DA VINCI study enrolled patients prescribed lipid-lowering therapy (LLT) between 21 June 2017 and 20 November 2018. Data for patients from Belgium were extracted for this country-specific analysis. Primary endpoint was the proportion of patients who achieved 2016 ESC/EAS risk-based LDL-C goals; attainment of 2019 risk-based LDL-C goals was evaluated post hoc. RESULTS: Of 497 enrolled patients, 41% were female and mean age was 68 years. Among subjects with an LDL-C measurement on stabilised LLT, moderate-intensity statin monotherapy was the most prescribed LLT regimen (59%). Overall, 63% of patients achieved their risk-based LDL-C goals according to the 2016 ESC/EAS guidelines. Among patients with established ASCVD, risk-based LDL-C goal attainment was higher in patients with peripheral arterial disease (53%) than patients with coronary (37%) and cerebrovascular disease (42%). According to the updated 2019 ESC/EAS guidelines, less than half (41%) of patients achieved their risk-based LDL-C goal. The proportion of primary and secondary prevention patients who achieved 2019 risk-based LDL-C goals was 59% and 18%, respectively. CONCLUSION: These findings reveal a large gap between the LDL-C goals advocated by the ESC/EAS and the levels achieved in routine clinical practice in Belgium.
RESUMEN
BACKGROUND: Dietary interventions targeting the gut microbiota have been proposed as innovative strategies to improve obesity-associated metabolic disorders. Increasing physical activity (PA) is considered as a key behavioral change for improving health. We have tested the hypothesis that changing the PA status during a nutritional intervention based on prebiotic supplementation can alter or even change the metabolic response to the prebiotic. We confirm in obese subjects and in high-fat diet fed mice that performing PA in parallel to a prebiotic supplementation is necessary to observe metabolic improvements upon inulin. METHODS: A randomized, single-blinded, multicentric, placebo-controlled trial was conducted in obese participants who received 16 g/day native inulin versus maltodextrin, coupled to dietary advice to consume inulin-rich versus -poor vegetables for 3 months, respectively, in addition to dietary caloric restriction. Primary outcomes concern the changes on the gut microbiota composition, and secondary outcomes are related to the measures of anthropometric and metabolic parameters, as well as the evaluation of PA. Among the 106 patients who completed the study, 61 patients filled a questionnaire for PA before and after intervention (placebo: n = 31, prebiotic: n = 30). Except the dietitian (who provided dietary advices and recipes book), all participants and research staff were blinded to the treatments and no advices related to PA were given to participants in order to change their habits. In parallel, a preclinical study was designed combining both inulin supplementation and voluntary exercise in a model of diet-induced obesity in mice. RESULTS: Obese subjects who increased PA during a 3 months intervention with inulin-enriched diet exhibited several clinical improvements such as reduced BMI (- 1.6 kg/m2), decreased liver enzymes and plasma cholesterol, and improved glucose tolerance. Interestingly, the regulations of Bifidobacterium, Dialister, and Catenibacterium genera by inulin were only significant when participants exercised more. In obese mice, we highlighted a greater gut fermentation of inulin and improved glucose homeostasis when PA is combined with prebiotics. CONCLUSION: We conclude that PA level is an important determinant of the success of a dietary intervention targeting the gut microbiota. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03852069 (February 22, 2019 retrospectively registered).
Asunto(s)
Inulina , Obesidad , Animales , Índice de Masa Corporal , Dieta Alta en Grasa , Ejercicio Físico , Humanos , Inulina/farmacología , Ratones , Obesidad/tratamiento farmacológico , Obesidad/metabolismoRESUMEN
(1) Background: Obesity and type 2 diabetes have been suspected to impact both intrinsic metabolism and function of circulating immune cells. (2) Methods: To further investigate this immunometabolic modulation, we profiled the phospholipidome of the peripheral blood mononuclear cells (PBMCs) in lean, normoglycemic obese (OBNG) and obese with dysglycemia (OBDysG) individuals. (3) Results: The global PBMCs phospholipidome is significantly downmodulated in OBDysG unlike OBNG patients when compared to lean ones. Multiple linear regression analyses show a strong negative relationship between the global PBMCs phospholipidome and parameters assessing insulin resistance. Even though all classes of phospholipid are affected, the relative abundance of each class is maintained with the exception of Lyso-PC/PC and Lyso-PE/PE ratios that are downmodulated in PBMCs of OBDysG compared to OBNG individuals. Interestingly, the percentage of saturated PC is positively associated with glycated hemoglobin (HbA1c). Moreover, a few lipid species are significantly downmodulated in PBMCs of OBDysG compared to OBNG individuals, making possible to distinguish the two phenotypes. (4) Conclusions: This lipidomic study highlights for the first-time modulations of the PBMCs phospholipidome in obese patients with prediabetes and type 2 diabetes. Such phospholipidome remodeling could disrupt the cell membranes and the lipid mediator's levels, driving an immune cell dysfunction.
Asunto(s)
Glucemia , Resistencia a la Insulina , Leucocitos Mononucleares/metabolismo , Lipidómica , Obesidad/metabolismo , Fosfolípidos/metabolismo , Adulto , Biomarcadores , Pesos y Medidas Corporales , Biología Computacional , Diabetes Mellitus Tipo 2/etiología , Diabetes Mellitus Tipo 2/metabolismo , Femenino , Hemoglobina Glucada/metabolismo , Humanos , Lipidómica/métodos , Masculino , Espectrometría de Masas , Lípidos de la Membrana , Persona de Mediana Edad , Obesidad/sangre , Obesidad/etiología , Adulto JovenRESUMEN
BACKGROUND: As cardiovascular diseases represent the main cause of non-AIDS related death in people living with HIV (PLWH) with undetectable viral load, we evaluated lipid profile, weight gain and calculated cardiovascular risk change after switching from tenofovir disoproxil fumarate (TDF)-based regimens to tenofovir alafenamide (TAF)-based regimens. METHODS: For this retrospective study, we selected HIV-infected patients with suppressed viral load who fitted in one of the two groups below: First group (TDF/TDF): Patients treated continuously with TDF-based regimens. Second group (TDF/TAF): Patients treated with TDF-regimens during at least 6 months then switched to TAF-regimens while maintaining other drugs unchanged. Available data included date of birth, gender, ethnicity, lymphocyte T CD4+ count, weight, height, blood pressure, current/ex/non-smoker, diabetes mellitus, familial cardiovascular event, lipid profile, duration and nature of antiretroviral therapy. Lipid parameters, weight and calculated cardiovascular risk using 5-year reduced DAD score algorithm [Friis-Møller et al. in Eur J Cardiovasc Prev Rehabil 17:491-501, 2010] were analyzed in each groups. RESULTS: Switching from TDF to TAF resulted in a significant increase in triglycerides levels, total cholesterol and HDL cholesterol. LDL cholesterol and total cholesterol/HDL ratio did not show significant changes. Calculated cardiovascular risk increased after switch from TDF- to TAF-based therapy. CONCLUSIONS: Together with favorable outcomes at the bone and kidney levels, potential negative impact of TAF on lipid profile should be included in the reflection to propose the most appropriate and tailored ARV treatment.
Asunto(s)
Fármacos Anti-VIH , Enfermedades Cardiovasculares , Infecciones por VIH , Alanina , Fármacos Anti-VIH/efectos adversos , Infecciones por VIH/complicaciones , Infecciones por VIH/tratamiento farmacológico , Factores de Riesgo de Enfermedad Cardiaca , Humanos , Lípidos , Estudios Retrospectivos , Factores de Riesgo , Tenofovir/análogos & derivados , Tenofovir/uso terapéutico , Aumento de PesoRESUMEN
People with diabetes are considered to have an increased cardiovascular risk. Patients with type 1 diabetes (T1D) generally have a cardiovascular risk profile that is different from those with type 2 diabetes. For this reason, we wanted to assess whether a population of T1D designed to be at very high cardiovascular risk achieved the strict goals recommended by the European Society of Cardiology. This is a descriptive cross-sectional analysis of a cohort of patients with T1D for at least 20 years followed at the University Hospital of Liege and considered to be at very high cardiovascular risk. We then discuss the relevance of strict targets in such patients by comparing them to different scientific societies. Finally, we briefly discuss the potential mechanisms by which T1D present an increased cardiovascular risk.
Les personnes diabétiques sont considérées comme ayant un risque cardiovasculaire accru. Les patients diabétiques de type 1 (DT1) ont un profil de risque cardiovasculaire souvent différent de celui des diabétiques de type 2. Nous avons évalué si une population de patients DT1, dits « à très haut risque cardiovasculaire ¼, atteignait les objectifs stricts recommandés par la Société européenne de cardiologie. Il s'agit d'une analyse transversale descriptive d'une cohorte de patients avec au moins 20 ans de DT1, suivis au CHU de Liège et considérés comme à très haut risque cardiovasculaire. Nous discutons de la pertinence de tels objectifs chez de tels patients, en les comparant à ceux de différentes sociétés savantes. Nous abordons brièvement les mécanismes potentiels à l'origine, dans ce groupe, d'un risque cardiovasculaire accru.
Asunto(s)
Enfermedades Cardiovasculares , Diabetes Mellitus Tipo 1 , Diabetes Mellitus Tipo 2 , Enfermedades Cardiovasculares/epidemiología , Enfermedades Cardiovasculares/etiología , Estudios Transversales , Diabetes Mellitus Tipo 1/complicaciones , Diabetes Mellitus Tipo 1/epidemiología , Factores de Riesgo de Enfermedad Cardiaca , Humanos , Factores de RiesgoRESUMEN
Glucagon-like peptide-1 receptor agonists are the antidiabetic agents that are associated with the greatest weight loss beyond a marked reduction in glycated haemoglobin. Weight loss results from a reduction in appetite through a predominant central effect combined with a peripheral effect. Liraglutide and semaglutide are developed for the treatment of obesity, independently of type 2 diabetes. Three approaches may be considered to potentiate weight loss: an increase of the drug dosage because of the demonstration of a dose-response, an add-on therapy with a sodium-glucose cotransporter type 2 inhibitor as this agent exerts a complementary action through urinary calorie loss (glucosuria) or a combination of the effects of two incretin hormones (GLP-1 and GIP), as the potent dual agonist tirzepatide currently in development.
Les agonistes des récepteurs du glucagon-like peptide-1 (GLP-1) sont les agents antidiabétiques qui, outre une baisse importante du taux d'hémoglobine glyquée, offrent la perte pondérale la plus marquée, en augmentant la satiété par un effet central, prédominant et périphérique. Le liraglutide et le sémaglutide sont développés pour le traitement de l'obésité, indépendamment de la présence d'un diabète de type 2. Trois approches sont possibles pour potentialiser la perte de poids: augmenter la posologie, compte tenu de l'existence d'une relation dose-réponse, ajouter un inhibiteur des sodium-glucose cotransporteurs 2 qui exerce un effet complémentaire grâce à une fuite calorique urinaire (glucosurie), ou encore combiner les effets de deux hormones incrétines (GLP-1 et Glucose-dependent Insulin Releasing Polypeptide), comme avec le puissant double agoniste tirzépatide en développement.
Asunto(s)
Diabetes Mellitus Tipo 2 , Preparaciones Farmacéuticas , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Péptido 1 Similar al Glucagón , Receptor del Péptido 1 Similar al Glucagón , Humanos , Pérdida de PesoRESUMEN
Sacubitril/valsartan, a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI), is indicated for the treatment of heart failure with reduced ejection fraction. It has demonstrated benefits in terms of cardiovascular morbidity and mortality reduction in this population. Recently, this drug association has also been shown to improve glycemic control and insulin sensitivity in patients with obesity and/or type 2 diabetes. Furthermore, some studies suggest a protective role of this new drug class in diabetic nephropathy. Altogether, these data raise the question about the potential place of ARNI in prevention and treatment of type 2 diabetes, a condition closely associated with heart failure.
Le sacubitril/valsartan, premier médicament de la classe des ARNI (Angiotensin Receptor-Neprilysin Inhibitor), est indiqué dans le traitement de l'insuffisance cardiaque à fraction d'éjection réduite. Il a démontré des bénéfices en termes de réduction de morbimortalité cardiovasculaire dans cette population. Récemment, il a également été rapporté que cette association thérapeutique améliore le contrôle glycémique et la sensibilité à l'insuline des patients avec une obésité et/ou un diabète de type 2. De plus, certaines études suggèrent également un rôle protecteur de cette nouvelle classe médicamenteuse dans la néphropathie diabétique. Ces données soulèvent la question de la place éventuelle des ARNI dans la prévention et le traitement du diabète de type 2, une pathologie étroitement associée à l'insuffisance cardiaque.
Asunto(s)
Diabetes Mellitus Tipo 2 , Aminobutiratos , Antagonistas de Receptores de Angiotensina/uso terapéutico , Compuestos de Bifenilo , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Combinación de Medicamentos , Humanos , Neprilisina , ValsartánRESUMEN
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic hepatic pathology in Western countries. It encompasses a spectrum of conditions ranging from simple steatosis to more severe and progressive non-alcoholic steatohepatitis (NASH) that can lead to hepatocellular carcinoma (HCC). Obesity and related metabolic syndrome are important risk factors for the development of NAFLD, NASH and HCC. DUSP3 is a small dual-specificity protein phosphatase with a poorly known physiological function. We investigated its role in metabolic syndrome manifestations and in HCC using a mouse knockout (KO) model. While aging, DUSP3-KO mice became obese, exhibited insulin resistance, NAFLD and associated liver damage. These phenotypes were exacerbated under high fat diet (HFD). In addition, DEN administration combined to HFD led to rapid HCC development in DUSP3-KO compared to wild type (WT) mice. DUSP3-KO mice had more serum triglycerides, cholesterol, AST and ALT compared to control WT mice under both regular chow diet (CD) and HFD. The level of fasting insulin was higher compared to WT mice, though, fasting glucose as well as glucose tolerance were normal. At the molecular level, HFD led to decreased expression of DUSP3 in WT mice. DUSP3 deletion was associated with increased and consistent phosphorylation of the insulin receptor (IR) and with higher activation of the downstream signaling pathway. In conclusion, our results support a new role for DUSP3 in obesity, insulin resistance, NAFLD and liver damage.